ISOVUE-200
Clinical safety rating
cautionComprehensive clinical and safety monograph for ISOVUE-200 (ISOVUE-200).
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
| Metabolism | Iopamidol is not metabolized; eliminated unchanged via glomerular filtration. |
| Excretion | Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination. |
| Half-life | 2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance. |
| Protein binding | <2% bound; negligible binding to plasma proteins. |
| Volume of Distribution | 0.24 L/kg; restricted to extracellular fluid, no intracellular penetration. |
| Bioavailability | Oral: 0% (not absorbed); IV/IA/Intrathecal: 100% (administered directly into blood/CSF). |
| Onset of Action | IV injection: immediate opacification (within seconds); intra-arterial: immediate during injection; intrathecal: within minutes. |
| Duration of Action | IV: 15-30 minutes for contrast enhancement; CT scanning optimal 5-10 min post-bolus. Intrathecal: up to 1-2 hours for CSF imaging. |
| Molecular Weight | 777.09 Da |
Intravenous administration of 1.0-2.0 mL/kg (200 mg iodine/mL) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 mL total. Maximum recommended dose: 2.0 mL/kg.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR <30 mL/min/1.73m²: Administer with caution, consider prophylaxis with hydration and N-acetylcysteine. eGFR <15: Use only if diagnostic benefit outweighs risk of contrast-induced nephropathy. No specific dose reduction established; consider using lowest feasible volume. |
| Liver impairment | No specific adjustments recommended for Child-Pugh class A, B, or C. Monitor renal function in patients with severe liver disease due to risk of hepatorenal syndrome. |
| Pediatric use | Neonates and infants: 1.5-2.0 mL/kg intravenously. Children: 1.0-2.0 mL/kg intravenously; maximum 2.0 mL/kg. For intra-arterial use, consult weight-based dosing guidelines. |
| Geriatric use | No specific dose adjustment required based on age alone. Assess renal function (eGFR) in elderly patients as age-related decline is common; follow renal adjustment guidelines. Ensure adequate hydration before and after administration. |
| 1st trimester | Avoid unless essential; iodinated contrast crosses placenta and fetal thyroid exposure may cause neonatal hypothyroidism. Risk-benefit assessment required. |
| 2nd trimester | Use only if clearly needed; fetal thyroid maturation begins at 10-12 weeks; potential hypothyroidism risk. Consider alternative imaging modalities. |
| 3rd trimester | Use only if essential; fetal thyroid is functional; neonatal hypothyroidism risk if high doses administered. Monitor neonatal thyroid function post-delivery. |
Clinical note
Comprehensive clinical and safety monograph for ISOVUE-200 (ISOVUE-200).
| Placental transfer | Iopamidol crosses the placenta. In animal studies, detectable levels were found in fetal tissues. The extent is low, but fetal thyroid exposure occurs due to free iodide release. |
| Breastfeeding | Iodinated contrast agents like iopamidol are excreted in breast milk in very small amounts (less than 1% of maternal dose). The risk to the nursing infant is negligible, but the manufacturer recommends discontinuation of breastfeeding for 24 hours post-administration as a precaution. Current guidelines suggest that breastfeeding can continue without interruption, but the mother may choose to pump and discard for 24 hours. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essential. Second and third trimesters: no known teratogenicity; neonatal thyroid function monitoring recommended after exposure. |
| Fetal Monitoring | Assess maternal renal function prior to administration. Monitor for anaphylactoid reactions. After in utero exposure, monitor neonatal thyroid function (TSH, T4) within first week of life. |
| Fertility Effects | No known adverse effects on fertility in males or females. |
■ FDA Black Box Warning
Not for intrathecal use with ISOVUE-200 (iopamidol injection 41%) due to risk of severe adverse reactions including seizures, paralysis, and death.
| Serious Effects |
History of clinically significant hypersensitivity reaction to iopamidol or other iodinated contrast agents
| Precautions | Risk of severe hypersensitivity reactions including anaphylaxis; acute kidney injury in patients with pre-existing renal impairment; CNS adverse effects including seizures with intrathecal administration; thyroid dysfunction in patients with hyperthyroidism; contrast-induced nephropathy. |
| Food/Dietary | No specific food interactions with ISOVUE-200. Patients are generally encouraged to hydrate with clear fluids before and after the procedure. There are no dietary restrictions. However, in patients with diabetes taking metformin, metformin should be withheld for 48 hours after contrast administration and only resumed after renal function is re-evaluated. |
| Clinical Pearls | ISOVUE-200 (iopamidol 41%) is a nonionic, low-osmolality iodinated contrast medium. It is indicated for intrathecal administration in myelography (lumbar, thoracic, cervical, total columnar) and for contrast enhancement in CT and angiocardiography. Key pearls: (1) Monitor renal function before administration due to risk of contrast-induced nephropathy; (2) Prehydrate patients with normal saline to reduce nephrotoxicity; (3) Have emergency equipment available for hypersensitivity reactions; (4) Avoid in patients with known iodine allergy or prior reaction to contrast; (5) Do not mix with other medications in the same syringe; (6) For intrathecal use, ensure proper patient positioning to minimize cephalad flow; (7) Use with caution in patients with sickle cell disease, pheochromocytoma, or hyperthyroidism. |
| Patient Advice | Inform your doctor if you have ever had an allergic reaction to iodine, contrast dye, or any medications. · Tell your healthcare provider if you have kidney disease, diabetes, asthma, heart disease, or thyroid problems. · You may need to stop taking certain medications (e.g., metformin) before the procedure; follow your doctor's instructions. · You will be asked to drink plenty of fluids before and after the procedure to protect your kidneys. · During injection, you may feel warmth, a metallic taste in the mouth, or nausea; these are usually temporary. · Report any severe symptoms such as difficulty breathing, hives, swelling, or chest pain immediately. · After the procedure, you may resume normal diet unless otherwise instructed. · Breastfeeding women should pump and discard breast milk for 24 hours after contrast administration. |
Loading safety data…